Overview

MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

Status:
Not yet recruiting
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, single-site phase II 2-arm study will investigate the safety and preliminary efficacy of MDMA-assisted therapy compared with low dose d-amphetamine-assisted therapy on the severity of PTSD symptoms in participants aged 18 years and older with PTSD of at least moderate severity.
Phase:
Phase 2
Details
Lead Sponsor:
Stephen Robert Marder
Treatments:
Amphetamine
Dextroamphetamine
N-Methyl-3,4-methylenedioxyamphetamine